GeronGERN
GERN
About: Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Employees: 141
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
198% more call options, than puts
Call options by funds: $15.4M | Put options by funds: $5.18M
70% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 27
42% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 60
17% more capital invested
Capital invested by funds: $1.98B [Q2] → $2.32B (+$330M) [Q3]
7% more funds holding
Funds holding: 238 [Q2] → 255 (+17) [Q3]
5.88% more ownership
Funds ownership: 78.74% [Q2] → 84.62% (+5.88%) [Q3]
17% less funds holding in top 10
Funds holding in top 10: 6 [Q2] → 5 (-1) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
142%
upside
Avg. target
$8
177%
upside
High target
$9
211%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Needham Gil Blum 16% 1-year accuracy 28 / 170 met price target | 142%upside $7 | Buy Maintained | 13 Jan 2025 |
HC Wainwright & Co. Emily Bodnar 13% 1-year accuracy 19 / 150 met price target | 211%upside $9 | Buy Reiterated | 10 Dec 2024 |
Financial journalist opinion
Positive
Seeking Alpha
4 days ago
Geron: Positive IMpactMF Trial Could Possibly Lead To Doubling Of RYTELO Sales
Geron Corporation's RYTELO received FDA approval for Low-Risk Myelodysplastic Syndrome and is awaiting European Medicines Agency approval as well, which might help to boost sales. Geron reported $28.2 million in the first full quarter of sales of RYTELO, with projections of $45-$46 million set for Q4 2024. Geron is conducting a Phase 3 study for RYTELO targeting JAK inhibitor relapsed/refractory Myelofibrosis patients, with interim results expected by early 2026 and final results early 2027.
Positive
Zacks Investment Research
1 week ago
Geron Stock Rallies More Than 60% in a Year: Here's Why
FDA's approval of GERN's Rytelo (imetelstat) for treating low- to intermediate-1 risk MDS drives the stock 61.1% higher in the past year.
Neutral
Business Wire
1 month ago
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 72,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on December 18, 2024, at an exercise price $3.77 per share, which is equal to the closing price of Geron common stock o.
Neutral
Business Wire
1 month ago
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of RYTELO (imetelstat) for the treatment of adult patients with transfusion-dependent (TD) anemia due to very low, low or intermediate risk myel.
Neutral
Business Wire
1 month ago
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced new analyses presented at the 66th American Society of Hematology (ASH) Annual Meeting from the IMerge clinical trial in patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia suggesting clinical activity of first-in-class telomerase inhibitor RYTELO™ (imetelstat).
Neutral
Business Wire
1 month ago
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced results from an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting, reporting Phase 1 findings from the two-part IMproveMF study. The safety results from the dose escalation Part 1 suggest the tolerability of RYTELO™ (imetelstat), a first-in-class telomerase inhibitor, in.
Neutral
Business Wire
1 month ago
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference, in Coral Gables, Florida on Wednesday, December 4, 2024, at 8:20 a.m. ET. A webcast of the fireside chat will be available through the Investors and Media section of Geron's website under Events following the presentation. The.
Neutral
Business Wire
1 month ago
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 1,017,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on November 20, 2024, at an exercise price $3.99 per share, which is equal to the closing price of Geron common stoc.
Positive
Seeking Alpha
1 month ago
Geron: A Strong Launch And Financial Deals Make It Attractive
Geron exceeded expectations with $28.2mn in Q1 revenue, surpassing analyst estimates and showcasing strong physician feedback and market potential for imetelstat. Analysts are bullish, with H.C. Wainwright, Leerink, and Goldman Sachs projecting significant sales growth and maintaining high price targets for Geron. Favorable funding deals with Royalty Pharma and Pharmakon Advisors provide $375mn, enhancing Geron's financial stability and supporting future commercialization efforts.
Neutral
Business Wire
2 months ago
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development, effective today, November 11, 2024. In this role, Dr. Eid will lead our Research and Development organization comprised of medical, clinical, and safety/pharmacovigilance teams and be responsible for driving inno.
Charts implemented using Lightweight Charts™